HC Wainwright Issues Positive Forecast for DTIL Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Precision BioSciences in a research report issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.82). The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.43) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($2.21) EPS.

Several other research firms also recently issued reports on DTIL. Wall Street Zen upgraded shares of Precision BioSciences from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Jefferies Financial Group reiterated a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a research note on Friday, March 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $39.50.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $6.50 on Monday. Precision BioSciences has a fifty-two week low of $3.53 and a fifty-two week high of $8.82. The company has a market cap of $160.62 million, a PE ratio of -1.27 and a beta of 1.28. The company has a debt-to-equity ratio of 0.24, a quick ratio of 13.32 and a current ratio of 13.32. The business has a 50-day simple moving average of $4.44 and a two-hundred day simple moving average of $5.05.

Insider Activity

In related news, CEO Michael Amoroso sold 20,559 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total transaction of $78,946.56. Following the completion of the transaction, the chief executive officer owned 243,392 shares of the company’s stock, valued at $934,625.28. This trade represents a 7.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider J. Jefferson Smith sold 10,200 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total transaction of $41,106.00. Following the transaction, the insider owned 110,184 shares of the company’s stock, valued at $444,041.52. This represents a 8.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,845 shares of company stock valued at $376,677 in the last ninety days. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its position in shares of Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after acquiring an additional 4,025 shares during the period. Bridgeway Capital Management LLC purchased a new stake in shares of Precision BioSciences in the second quarter valued at approximately $260,000. Corient Private Wealth LLC purchased a new stake in shares of Precision BioSciences in the second quarter valued at approximately $425,000. Vanguard Personalized Indexing Management LLC acquired a new position in Precision BioSciences during the third quarter worth $72,000. Finally, Vanguard Group Inc. raised its position in shares of Precision BioSciences by 21.5% during the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock worth $2,719,000 after purchasing an additional 87,242 shares during the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.